ES2126563T3 - Uso de compuestos inhibidores de prolactina para reajuste del ritmo circadiano de prolactina. - Google Patents
Uso de compuestos inhibidores de prolactina para reajuste del ritmo circadiano de prolactina.Info
- Publication number
- ES2126563T3 ES2126563T3 ES91300083T ES91300083T ES2126563T3 ES 2126563 T3 ES2126563 T3 ES 2126563T3 ES 91300083 T ES91300083 T ES 91300083T ES 91300083 T ES91300083 T ES 91300083T ES 2126563 T3 ES2126563 T3 ES 2126563T3
- Authority
- ES
- Spain
- Prior art keywords
- prolactin
- long term
- treatment
- peak
- bromocriptine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000003946 Prolactin Human genes 0.000 title abstract 3
- 108010057464 Prolactin Proteins 0.000 title abstract 3
- 230000027288 circadian rhythm Effects 0.000 title abstract 3
- 229940097325 prolactin Drugs 0.000 title abstract 3
- 229940123796 Prolactin inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 4
- 230000007774 longterm Effects 0.000 abstract 3
- 241000894007 species Species 0.000 abstract 3
- 206010060378 Hyperinsulinaemia Diseases 0.000 abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 2
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 abstract 2
- 229960002802 bromocriptine Drugs 0.000 abstract 2
- 201000001421 hyperglycemia Diseases 0.000 abstract 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 abstract 2
- 201000008980 hyperinsulinism Diseases 0.000 abstract 2
- 238000002347 injection Methods 0.000 abstract 2
- 239000007924 injection Substances 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 241000282414 Homo sapiens Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 1
- 210000000577 adipose tissue Anatomy 0.000 abstract 1
- 230000036765 blood level Effects 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 abstract 1
- 239000003862 glucocorticoid Substances 0.000 abstract 1
- 230000003054 hormonal effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000028503 regulation of lipid metabolic process Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2257—Prolactin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
UN PROCESO PARA LA MODIFICACION A LARGO PLAZO Y REGULACION DEL METABOLISMO DE LOS LIPIDOS -GENERALMENTE PARA REDUCIR LA OBESIDAD, RESISTENTE A LA INSULINA, A LA HIPERINSULINEMIA O HIPERGLICEMIA, O A AMBAS (ESTAS SON LAS MARCAS DEL CONTRASTE DE LOS NO DEPENDIENTES DE LA INSULINA O DE LA DIABETES TIPO II) POR ADMINISTRACION (POR EJ: MEDIANTE ALIMENTACION O INYECCION EN LA CORRIENTE SANGUINEA) A UN VERTEBRADO ANIMAL O HUMANO DE DOPAMINA AGONISTA, POR EJ: BROMOCRIPTINA. SE ADMINISTRA LA BROMOCRIPTINA SOBRE UN PERIODO LIMITADO DE UNA VEZ AL DIA DEPENDIENDO DEL RITMO CIRCADIANO NORMAL DE LOS MIEMBROS GRUESOS Y DELGADOS DE ESPECIES SIMILARES. EL TRATAMIENTO DARA COMO RESULTADO UNA DISMINUCION DE LAS GRASAS DEL CUERPO DE LA ESPECIE OBESA EN UNA SECUENCIA DIARIA DE TIEMPO BASADA EN LOS RITMOS CIRCADIANOS DE LA PROLACTINA MAXIMA, O DE LA PROLACTINA MAXIMA Y EL GLUCOCORTICOSTEROIDE MAXIMO, DEL NIVEL DE LA SANGRE ESTABLECIDO PARA LOS MIEMBROS DELGADOS DE ESPECIES SIMILARES, LA RESISTENCIA A LA INSULINAE HIPERINSULINEMIA E HIPERGLICEMIA, O AMBAS, PODRAN CONTROLARSE TAMBIEN EN LOS HUMANOS POR UN TRATAMIENTO BASE A LARGO TIEMPO CORRESPONDIENTE A AQUEL PARA LA OBESIDAD. LAS INYECCIONES DIARIAS DE CORTO TIEMPO VUELVEN A FIJAR UN TIEMPO HORMONAL EN LOS CENTROS NEURALES DEL CEREBRO PARA PRODUCIR EFECTOS DE LARGO TIEMPO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46332790A | 1990-01-10 | 1990-01-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2126563T3 true ES2126563T3 (es) | 1999-04-01 |
Family
ID=23839717
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES91300083T Expired - Lifetime ES2126563T3 (es) | 1990-01-10 | 1991-01-07 | Uso de compuestos inhibidores de prolactina para reajuste del ritmo circadiano de prolactina. |
ES98110831T Expired - Lifetime ES2306465T3 (es) | 1990-01-10 | 1991-01-07 | Procedimiento para la reduccion a largo plazo de almacenes de grasa corporal,resistencia a insulina,hiperinsulinemia e hiperglucemia en vertebrados. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES98110831T Expired - Lifetime ES2306465T3 (es) | 1990-01-10 | 1991-01-07 | Procedimiento para la reduccion a largo plazo de almacenes de grasa corporal,resistencia a insulina,hiperinsulinemia e hiperglucemia en vertebrados. |
Country Status (9)
Country | Link |
---|---|
US (2) | US5496803A (es) |
EP (2) | EP0917874B1 (es) |
JP (2) | JP2896939B2 (es) |
AT (2) | ATE174793T1 (es) |
CA (1) | CA2030174C (es) |
DE (2) | DE69133595T2 (es) |
DK (2) | DK0440333T3 (es) |
ES (2) | ES2126563T3 (es) |
GR (1) | GR3029276T3 (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5344832A (en) * | 1990-01-10 | 1994-09-06 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates |
US5716932A (en) * | 1988-05-10 | 1998-02-10 | Louisiana State University And Agricultural And Mechanical College | Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates |
US5744477A (en) * | 1988-05-10 | 1998-04-28 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method for treatment of obesity using prolactin modulators and diet |
US5792748A (en) * | 1995-06-07 | 1998-08-11 | The General Hospital Corporation | Method for inhibiting neoplastic disease in mammals |
CA2219978C (en) * | 1995-06-07 | 2011-02-01 | Ergo Science Incorporated | Method for inhibiting neoplastic disease in mammals |
ES2205215T3 (es) * | 1996-05-01 | 2004-05-01 | The General Hospital Corporation Doing Business As Massachusetts General Hospital | Inhibicion del crecimiento y erradicacion de tumores solidos usando un modulador de prolactina y un fotosensibilizador. |
US5866546A (en) * | 1997-04-18 | 1999-02-02 | Hadasit Medical Research Services And Development Company Ltd. | Treatment for diabetes |
WO2000000195A1 (en) | 1998-06-30 | 2000-01-06 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for the treatment of diabetes |
JP2003512038A (ja) * | 1999-10-19 | 2003-04-02 | キュラジェン コーポレイション | 肥満に関連した遺伝子および肥満に関連した遺伝子を使用するための方法 |
WO2001028540A2 (en) * | 1999-10-19 | 2001-04-26 | Glaxo Group Limited | Agent for treating cephalic pain |
WO2001028539A2 (en) * | 1999-10-19 | 2001-04-26 | Glaxo Group Limited | Agent for treating cephalic pain |
NO328803B1 (no) * | 2000-03-03 | 2010-05-18 | Thia Medica | Nye fettsyreanaloger |
US7067557B2 (en) * | 2000-05-26 | 2006-06-27 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
US6867183B2 (en) * | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
JP3674518B2 (ja) | 2001-03-06 | 2005-07-20 | 船井電機株式会社 | トラックジャンプ制御装置およびトラックジャンプ方法 |
US6828305B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828297B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6713452B2 (en) * | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7713932B2 (en) | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
US6858580B2 (en) * | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7196059B2 (en) * | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
US20040220190A1 (en) * | 2002-07-29 | 2004-11-04 | Cincotta Anthony H. | Methods of treating metabolic syndrome using dopamine receptor agonists |
US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
US20080200453A1 (en) | 2002-07-29 | 2008-08-21 | Cincotta Anthony H | Methods of treating metabolic syndrome using dopamine receptor agonists |
US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
US20040115754A1 (en) * | 2002-12-11 | 2004-06-17 | Umax Data Systems Inc. | Method for establishing a long-term profile of blood sugar level aiding self-control of the same |
TW200411178A (en) * | 2002-12-31 | 2004-07-01 | Veutron Corp | Method for determining the resolution of blood glucose by using rising time curve |
TW592667B (en) * | 2003-04-04 | 2004-06-21 | Veutron Corp | Method for determining the resolution of blood glucose |
EP2626368B1 (en) * | 2004-07-19 | 2016-12-21 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
ES2384641T3 (es) | 2005-07-14 | 2012-07-10 | Lithera, Inc. | Formulación lipolítica que potencia la liberación mantenida para el tratamiento localizado del tejido adiposo |
JP2010506941A (ja) * | 2006-10-17 | 2010-03-04 | リセラ,インク. | 甲状腺眼症の治療のための方法、組成物及び製剤 |
US20100035886A1 (en) * | 2007-06-21 | 2010-02-11 | Veroscience, Llc | Parenteral formulations of dopamine agonists |
US8741918B2 (en) | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
WO2008157845A1 (en) | 2007-06-21 | 2008-12-24 | Veroscience, Llc | Method of treating metabolic disorders and depression with dopamine receptor agonists |
AU2008313248B2 (en) * | 2007-10-16 | 2012-04-26 | Biocon Limited | An orally administerable solid pharmaceutical composition and a process thereof |
WO2009062113A1 (en) * | 2007-11-07 | 2009-05-14 | Burnham Institute For Medical Research | Method and compounds for modulating insulin production |
US9132084B2 (en) * | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
KR20120113267A (ko) * | 2010-01-15 | 2012-10-12 | 리쎄라 인코오포레이티드 | 동결건조 케이크 제제 |
EA201270784A1 (ru) | 2010-11-24 | 2013-04-30 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" | Монотерапевтические композиции селективного липофильного и бета-агониста длительного действия и способы косметического лечения ожирения и контурного выпячивания |
US8431155B1 (en) | 2012-04-30 | 2013-04-30 | Veroscience Llc | Bromocriptine formulations |
PL3445362T3 (pl) | 2016-04-20 | 2022-05-30 | Veroscience Llc | Kompozycja i sposób leczenia zaburzeń metabolicznych |
CA3079522A1 (en) | 2017-10-18 | 2019-04-25 | Veroscience Llc | Improved bromocriptine formulations |
WO2021061818A1 (en) | 2019-09-23 | 2021-04-01 | Veroscience Llc | Method for inducing tumor regression |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3074847A (en) * | 1960-04-27 | 1963-01-22 | Frank L Bigsby | Appetite control composition |
CH507249A (de) * | 1968-05-31 | 1971-05-15 | Sandoz Ag | Verfahren zur Herstellung von 2-Brom-a-ergokryptin |
US3922347A (en) * | 1974-12-19 | 1975-11-25 | Lilly Co Eli | Method of inhibiting prolactin secretion with 8-acylaminoergolenes |
US4054660A (en) * | 1975-04-14 | 1977-10-18 | Eli Lilly And Company | Method of inhibiting prolactin |
IT1157365B (it) * | 1977-10-24 | 1987-02-11 | Sandoz Ag | Medicamenti per trattare l'obesita' o ridurre il peso del corpo |
CA1153764A (en) * | 1980-02-25 | 1983-09-13 | Jehan F. Bagli | 2-(1-piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives |
BE890369A (fr) * | 1980-09-18 | 1982-03-16 | Sandoz Sa | Nouveaux medicaments a base d'inhibiteurs de la secretion de la prolactine pour le traitement de l'arteriosclerose |
GB8426922D0 (en) * | 1984-10-24 | 1984-11-28 | Sandoz Ltd | Galenic formulation |
US4659715A (en) * | 1986-03-07 | 1987-04-21 | Louisiana State University And Agricultural And Mechanical College | Method of inhibiting body fat stores |
US4783469A (en) * | 1986-03-07 | 1988-11-08 | Meier Albert H | Method of inhibiting body fat stores |
US4749709A (en) * | 1986-03-07 | 1988-06-07 | Louisiana State University And Agricultural And Mechanical College | Method of inhibiting body fat stores |
DE3722383A1 (de) * | 1986-07-14 | 1988-01-28 | Sandoz Ag | Neue verwendung von bromocriptin |
US5006526A (en) * | 1988-10-17 | 1991-04-09 | Louisiana State University | Method of treating a vertebrate animal to reduce plasma triglycerides and cholesterol levels and to alleviate and prevent atherosclerosis |
IT1235053B (it) * | 1989-04-07 | 1992-06-17 | Poli Ind Chimica Spa | Metodi per la preparazione di composizioni farmaceutiche a base di bromocriptina dotate di elevata stabilita' e prodotti derivanti. |
-
1990
- 1990-11-16 CA CA002030174A patent/CA2030174C/en not_active Expired - Lifetime
-
1991
- 1991-01-07 DK DK91300083T patent/DK0440333T3/da active
- 1991-01-07 ES ES91300083T patent/ES2126563T3/es not_active Expired - Lifetime
- 1991-01-07 DE DE69133595T patent/DE69133595T2/de not_active Expired - Lifetime
- 1991-01-07 ES ES98110831T patent/ES2306465T3/es not_active Expired - Lifetime
- 1991-01-07 EP EP98110831A patent/EP0917874B1/en not_active Expired - Lifetime
- 1991-01-07 DK DK98110831T patent/DK0917874T3/da active
- 1991-01-07 AT AT91300083T patent/ATE174793T1/de not_active IP Right Cessation
- 1991-01-07 EP EP91300083A patent/EP0440333B1/en not_active Expired - Lifetime
- 1991-01-07 AT AT98110831T patent/ATE391506T1/de not_active IP Right Cessation
- 1991-01-07 DE DE69130651T patent/DE69130651T2/de not_active Expired - Lifetime
- 1991-01-10 JP JP3065737A patent/JP2896939B2/ja not_active Expired - Lifetime
-
1994
- 1994-08-08 US US08/287,066 patent/US5496803A/en not_active Expired - Lifetime
-
1995
- 1995-06-06 US US08/465,818 patent/US5866584A/en not_active Expired - Lifetime
-
1997
- 1997-07-02 JP JP9177080A patent/JPH1072372A/ja active Pending
-
1999
- 1999-02-03 GR GR990400356T patent/GR3029276T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
JPH0748257A (ja) | 1995-02-21 |
ATE391506T1 (de) | 2008-04-15 |
DE69133595D1 (de) | 2008-05-21 |
ES2306465T3 (es) | 2008-11-01 |
DE69130651T2 (de) | 1999-05-06 |
US5496803A (en) | 1996-03-05 |
ATE174793T1 (de) | 1999-01-15 |
DK0440333T3 (da) | 1999-08-23 |
DE69133595T2 (de) | 2009-06-10 |
US5866584A (en) | 1999-02-02 |
DE69130651D1 (de) | 1999-02-04 |
CA2030174A1 (en) | 1991-07-11 |
GR3029276T3 (en) | 1999-05-28 |
JP2896939B2 (ja) | 1999-05-31 |
EP0440333B1 (en) | 1998-12-23 |
EP0917874B1 (en) | 2008-04-09 |
EP0440333A2 (en) | 1991-08-07 |
JPH1072372A (ja) | 1998-03-17 |
EP0917874A1 (en) | 1999-05-26 |
DK0917874T3 (da) | 2008-07-28 |
EP0440333A3 (en) | 1992-06-17 |
CA2030174C (en) | 1996-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2126563T3 (es) | Uso de compuestos inhibidores de prolactina para reajuste del ritmo circadiano de prolactina. | |
Turek et al. | Effects of age on the circadian system | |
US5719160A (en) | Method for modifying and regulating lipid metabolism | |
DE69132688T2 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
KR910004187A (ko) | 세트랄린을 사용한 조기사정의 치료방법 | |
KR950703951A (ko) | 광학적으로 순수한 r-케토로락을 포함하는 조성물과 무통과 해열치료에 이를 사용하는 방법(antipyretic and analgesic methods and compositions containing optically pure r-ketorolac) | |
US5792748A (en) | Method for inhibiting neoplastic disease in mammals | |
Fortier et al. | Functional interrelationships between the adenohypophysis, thyroid, adrenal cortex and gonads. | |
ATE290863T1 (de) | Verwendung von prolactinmodulatoren und diät zur herstellung eines medikamentes zur behandlung der fettleibigkeit | |
US5700800A (en) | Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound | |
LEE et al. | Incidence of prolonged pain relief following acupuncture | |
Smith et al. | Rat self administration of ethanol: Enhancement by darkness and exogenous melatonin | |
RU93058520A (ru) | Способы модификации и регулирования метаболизма липидов и глюкозы у животных или человека, способы модификации и регулирования нервных фазовых ритмов человека, способ модификации и регулирования нервных фазовых колебаний головного мозга | |
NO934763L (no) | Fremgangsmåte ved langtidsreduksjon av kroppens fettlagre, insulinresistens, hyperinsulinemi og hyperglycemi hos virveldyr | |
Sˇusˇić et al. | The effects of delta-sleep-inducing peptide (DSIP) on wakefulness and sleep patterns in the cat | |
Wirz-Justice et al. | Circadian feeding rhythms: central mechanisms and methamphetamine modulation | |
SU1656581A1 (ru) | Способ моделировани агрессивного состо ни | |
RU96115219A (ru) | Способ лечения больных сахарным диабетом | |
Ignatov et al. | The analgetic activity of antidepressants and their influence on the pain-relieving effect of acupuncture | |
Park | Bromocriptine: a place in Parkinson's disease? | |
RU97114239A (ru) | Способ лечения инсулинзависимого диабета /i-тип/ | |
Mori et al. | Mid-pontine evoked postural changes and locomotor activity in an intact cat without restraint | |
Fujimoto et al. | Mechanism of feeding suppression induced by 1-deoxyglucosamine | |
RU97114238A (ru) | Способ лечения инсулиннезависимого сахарного диабета 2-го типа, сопровождающегося ожирением |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 440333 Country of ref document: ES |